trending Market Intelligence /marketintelligence/en/news-insights/trending/zbas0dc9vpdgqgmjxxt8hg2 content esgSubNav
In This List

Sarepta Therapeutics adds director

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Sarepta Therapeutics adds director

Sarepta Therapeutics Inc. has appointed Mary Ann Gray to the board.

Gray is president of Gray Strategic Advisors LLC, a biotechnology strategic planning and advisory firm. Previously, she was on the boards of Senomyx Inc., Juniper Pharmaceuticals Inc., TetraLogic Pharmaceuticals Corp. and ACADIA Pharmaceuticals Inc.

Cambridge, Mass.-based Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics, gene therapy and other genetic medicine approaches for treating rare neuromuscular diseases.